(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with slv 319 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhawas, A; Goswami, A; Gugale, SB; Jain, MR; Joharapurkar, A; Kadam, P; Kar, SS; Mishra, B; Mitra, P; Patel, JZ; Patel, PR; Sadhwani, N; Sairam, KV; Salunke, RP; Shedage, SA; Soni, R; Srivastava, BK; Unadkat, VB | 1 |
1 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and slv 319
| Article | Year |
|---|---|
Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole.
Topics: Animals; Combinatorial Chemistry Techniques; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Models, Molecular; Molecular Structure; Oxazoles; Pyrazoles; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Sulfonamides | 2008 |